MedTrace Logo

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

NCT06447701 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2025-07-28

No results posted yet for this study

Summary

IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.

Conditions

  • Brain Diseases
  • Ischemic Stroke
  • Ischemia
  • Stroke
  • Cerebral Infarction
  • Atherosclerosis of Artery
  • Atheroscleroses, Intracranial

Interventions

DRUG

Tocilizumab

Single dose intravenous application

DRUG

NaCl 0.9% 100ml

Single dose intravenous application

Sponsors & Collaborators

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Central People's Hospital of Zhanjiang

    collaborator OTHER

  • Shantou Central Hospital

    collaborator OTHER

  • Eighth Affiliated Hospital, Sun Yat-sen University

    collaborator OTHER

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Zhujiang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2025-12-31
Completion
2029-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06447701 on ClinicalTrials.gov